Kiniksa Pharmaceuticals International (KNSA) Competitors

$76.06 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$75.62 -0.44 (-0.57%)

As of 07:38 AM Eastern

KNSA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? MarketBeat compares Kiniksa Pharmaceuticals International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiniksa Pharmaceuticals International include BioNTech (BNTX), United Therapeutics (UTHR), Moderna (MRNA), Genmab A/S (GMAB), and BridgeBio Pharma (BBIO). These companies are all part of the "biotechnology" industry.

How does Kiniksa Pharmaceuticals International compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, BioNTech had 17 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 24 mentions for BioNTech and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat BioNTech's score of -0.11 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	8 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to BioNTech's net margin of -63.54%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.30	-$1.29B	-$7.83	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.76	$59.01M	$0.97	78.41

BioNTech presently has a consensus price target of $127.81, suggesting a potential upside of 36.45%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, suggesting a potential upside of 14.88%. Given BioNTech's higher probable upside, equities analysts clearly believe BioNTech is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

BioNTech has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats BioNTech on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

United Therapeutics has higher revenue and earnings than Kiniksa Pharmaceuticals International. United Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.26	$1.33B	$27.95	19.28
Kiniksa Pharmaceuticals International	$677.56M	8.76	$59.01M	$0.97	78.41

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, United Therapeutics had 26 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 33 mentions for United Therapeutics and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat United Therapeutics' score of 0.68 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	14 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. United Therapeutics' return on equity of 20.18% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

United Therapeutics currently has a consensus target price of $646.00, suggesting a potential upside of 19.89%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 14.88%. Given United Therapeutics' higher probable upside, equities research analysts plainly believe United Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

United Therapeutics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

Summary

United Therapeutics beats Kiniksa Pharmaceuticals International on 11 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Moderna?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Moderna's net margin of -141.43%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Moderna	-141.43%	-28.30%	-19.39%

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.76	$59.01M	$0.97	78.41
Moderna	$1.94B	12.15	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 49 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 56 mentions for Moderna and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat Moderna's score of 0.49 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	21 Very Positive mention(s)	8 Positive mention(s)	15 Neutral mention(s)	7 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, Moderna has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus price target of $87.38, suggesting a potential upside of 14.88%. Moderna has a consensus price target of $42.13, suggesting a potential downside of 28.79%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, equities analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Moderna	5 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	1.88

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Kiniksa Pharmaceuticals International beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Genmab A/S has a net margin of 19.08% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Genmab A/S's return on equity of 14.89% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Genmab A/S	19.08%	14.89%	7.73%

Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $87.38, suggesting a potential upside of 14.88%. Genmab A/S has a consensus target price of $39.50, suggesting a potential upside of 26.40%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Genmab A/S had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for Genmab A/S and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat Genmab A/S's score of 0.53 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	8.76	$59.01M	$0.97	78.41
Genmab A/S	$3.72B	5.24	$963M	$1.27	24.61

Summary

Genmab A/S beats Kiniksa Pharmaceuticals International on 9 of the 16 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

BridgeBio Pharma has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.89	-$724.93M	-$3.74	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.76	$59.01M	$0.97	78.41

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to BridgeBio Pharma's net margin of -124.42%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

BridgeBio Pharma presently has a consensus price target of $97.33, suggesting a potential upside of 15.21%. Kiniksa Pharmaceuticals International has a consensus price target of $87.38, suggesting a potential upside of 14.88%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.82
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 2 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 9 mentions for BridgeBio Pharma and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat BridgeBio Pharma's score of 0.87 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.93B	$3.69B	$7.00B	$12.99B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	78.41	9.02	270.61	25.05
Price / Sales	8.76	1,287.31	657.91	107.93
Price / Cash	95.82	44.95	28.89	37.44
Price / Book	10.22	17.69	11.26	6.43
Net Income	$59.01M	-$13.25M	$3.45B	$348.10M
7 Day Performance	3.61%	5.04%	3.41%	2.66%
1 Month Performance	19.89%	-2.10%	-0.71%	-0.85%
1 Year Performance	136.58%	61.50%	77.43%	23.96%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	4.1659 of 5 stars	$76.06 flat	$87.38 +14.9%	+136.6%	$5.93B	$677.56M	78.41	220	Positive News Gap Up
BNTX BioNTech	3.8565 of 5 stars	$91.19 -1.1%	$127.81 +40.2%	-16.1%	$23.06B	$2.65B	N/A	7,807	Analyst Downgrade
UTHR United Therapeutics	4.4315 of 5 stars	$532.94 +2.7%	$646.00 +21.2%	+78.7%	$22.62B	$3.18B	19.67	1,400	Trending News Earnings Report High Trading Volume
MRNA Moderna	1.3628 of 5 stars	$53.86 -4.3%	$42.13 -21.8%	+126.5%	$21.50B	$2.21B	N/A	4,700	Trending News Gap Down
GMAB Genmab A/S	4.7165 of 5 stars	$29.83 +1.9%	$39.28 +31.7%	+45.8%	$18.60B	$3.90B	22.60	3,029	Trending News Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

How does Kiniksa Pharmaceuticals International compare to BioNTech?

Summary

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

Summary

How does Kiniksa Pharmaceuticals International compare to Moderna?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. BNTX, UTHR, MRNA, GMAB, and BBIO

How does Kiniksa Pharmaceuticals International compare to BioNTech?

Does the media prefer BNTX or KNSA?

Do insiders and institutionals believe in BNTX or KNSA?

Is BNTX or KNSA more profitable?

Which has preferable earnings & valuation, BNTX or KNSA?

Do analysts prefer BNTX or KNSA?

Which has more risk and volatility, BNTX or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to United Therapeutics?

Which has stronger valuation & earnings, UTHR or KNSA?

Do institutionals & insiders believe in UTHR or KNSA?

Does the media prefer UTHR or KNSA?

Is UTHR or KNSA more profitable?

Do analysts prefer UTHR or KNSA?

Which has more risk & volatility, UTHR or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Moderna?

Is KNSA or MRNA more profitable?

Which has stronger earnings and valuation, KNSA or MRNA?

Does the media refer more to KNSA or MRNA?

Which has more risk and volatility, KNSA or MRNA?

Do analysts prefer KNSA or MRNA?

Do institutionals and insiders hold more shares of KNSA or MRNA?

Summary

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Is KNSA or GMAB more profitable?

Which has more volatility and risk, KNSA or GMAB?

Do analysts prefer KNSA or GMAB?

Does the media favor KNSA or GMAB?

Do institutionals & insiders have more ownership in KNSA or GMAB?

Which has preferable earnings and valuation, KNSA or GMAB?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Which has more risk and volatility, BBIO or KNSA?

Which has preferable earnings and valuation, BBIO or KNSA?

Is BBIO or KNSA more profitable?

Do analysts recommend BBIO or KNSA?

Do insiders & institutionals hold more shares of BBIO or KNSA?

Does the media prefer BBIO or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools